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PPARg is the master regulator of adipogenesis
and the molecular target of the thiazolidine-
dione antidiabetic drugs. By screening for
compounds that promote adipogenesis, we
identified a small molecule that targets the
PPARg pathway by a distinct mechanism. This
molecule, harmine, is not a ligand for the recep-
tor; rather, it acts as a cell-type-specific regula-
tor of PPARg expression. Administration of
harmine to diabetic mice mimics the effects of
PPARg ligands on adipocyte gene expression
and insulin sensitivity. Unlike thiazolidine-
diones, however, harmine does not cause
significant weight gain or hepatic lipid accumu-
lation. Molecular studies indicate that harmine
controls PPARg expression through inhibition
of the Wnt signaling pathway. This work vali-
dates phenotypic screening of adipocytes as a
promising strategy for the identification of bio-
active small molecules and suggests that regu-
lators of PPARg expression may represent a
complementary approach to PPARg ligands in
the treatment of insulin resistance.
INTRODUCTION
Type 2 diabetes is a major cause of morbidity and an
important risk factor for cardiovascular disease, cerebral
infarction, blindness, and kidney failure. The prevalence
of type 2 diabetes is increasing worldwide, and it is esti-
mated that more than 366 million people will be affected
by 2030 (Smyth and Heron, 2006). The primary factor un-
derlying this increase is a rapid rise in the prevalence of
obesity and obesity-related insulin resistance. At present,
thiazolidinediones (TZDs) are the principal class of drugs
available for improvement of insulin sensitivity in obese
diabetic subjects (Smyth and Heron, 2006). TZDs are
potent agonists for peroxisome proliferator-activatedCreceptor g (PPARg), a central regulator of adipocyte
gene expression and differentiation (Lehmann et al.,
1995; Tontonoz et al., 1994). Although their precise mech-
anism of action is still the subject of intense research,
TZDs are believed to exert their antidiabetic action in large
measure by inducing the expression of adipocyte PPARg
target genes involved in lipid and glucose metabolism
such as CD36 and adiponectin (Adipoq) (Lehrke and
Lazar, 2005).
Despite their efficacy, the development and clinical use
of PPARg ligands is limited by adverse effects such as
fluid retention, weight gain, congestive heart failure, liver
toxicity, and the potential for carcinogenesis (Berger
et al., 2005; Lehrke and Lazar, 2005; Nesto et al., 2003;
Yki-Jarvinen, 2004). Alternative approaches to the treat-
ment of insulin resistance are therefore needed. Current
attempts to develop safer insulin sensitizers are focused
largely on the optimization of PPAR ligands that possess
partial or gene-selective agonistic activity or the ability to
bind multiple PPAR family members (Berger et al., 2005;
Moller and Kaufman, 2005; Yki-Jarvinen, 2004). Since
PPARg agonists ameliorate obesity-related insulin resis-
tance by inducing PPAR target genes in adipocytes, we
speculated that small molecules that promote adipocyte
differentiation and/or regulate PPARg target genes by
distinct mechanisms could be candidates for novel insulin
sensitizers.
We describe here the development and validation of
a high-throughput screen for the identification of bio-
active small molecules based on an in vitro adipocyte
differentiation assay. Using this approach, we identified
an adipogenic small molecule, harmine, that regulates
expression of the key adipogenic factor PPARg. More-
over, we demonstrate that the ability of harmine to
control PPARg expression in adipocytes correlates with
antidiabetic action in vivo. Harmine mimics the effects
of PPARg ligands on PPARg-dependent gene expres-
sion in white adipose tissue and improves glucose
tolerance in diabetic mice. Small-molecule regulators
of PPARg expression may represent a complementary
approach to PPARg ligands in the treatment of insulin
resistance.ell Metabolism 5, 357–370, May 2007 ª2007 Elsevier Inc. 357
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Small-Molecule Regulator of PPARg ExpressionFigure 1. Identification of Small-Molecule Regulators of Adipogenesis by High-Throughput Cell-Based Screening
(A) Induction of luciferase activity during the differentiation of a stable reporter cell line, F442-luc20. Luciferase activity was determined after stimu-
lation of F442-luc20 cells with the PPARg ligand GW7845 (1 mM) as indicated.
(B and C) Histogram (left) and scatter plot (right) of the results from screening of the BIOMOL library in 96-well format for activators (B) or inhibitors (C)
of differentiation. The library and insulin (5 mg/ml) were added to F442-luc20 cells 1 day before and on the day of confluence, respectively. For the
inhibitor screen (C), GW7845 (10 nM) was added to the cells along with insulin. Luciferase was measured on day 5 after confluence and is shown
in log scale. PD98059 and GW7845 were used as controls for activators, and GW9662 was used as a control for inhibitors. Compounds with activity
more than 2.5 standard deviations from the mean (cutoff indicated by horizontal line) were chosen as initial positives.
(D and E) Oil red O staining of 3T3-F442A (D) and 3T3-L1 cells (E) after stimulation of differentiation by GW7845, harmine, RG14620, or PP1 at the
indicated concentrations for 6 days with or without insulin (5 mg/ml) or dexamethasone (1 mM, first 2 days only) as indicated. In 3T3-L1 differentiation
(E), GW7845 was used at 10 nM concentration, and all other compounds were used at 10 mM.RESULTS
A Cell-Based Screen for Small-Molecule Regulators
of Adipogenesis
To identify small-molecule inducers of differentiation, we
generated a 3T3-F442A reporter cell line (F442-luc20)
that stably expressed luciferase under the control of the
differentiation-dependent 5.4 kb aP2 promoter (Ross
et al., 1990). Luciferase activity in this cell line was induced
up to 50-fold following stimulation of differentiation by the
PPARg agonist GW7845 (Willson et al., 2000) for 6 days
(Figure 1A). This cell line was a sensitive reporter of
proadipogenic small molecules such as GW7845 and
PD98059 (Hu et al., 1996), as well as antiadipogenic mol-
ecules such as the PPARg antagonist GW9662 (Willson
et al., 2000) when assayed in 96-well or 384-well format358 Cell Metabolism 5, 357–370, May 2007 ª2007 Elsevier Inc.(Figures 1B and 1C and data not shown). We used
F442-luc20 cells to screen chemical libraries in con-
junction with the UCLA Molecular Screening Shared
Resource. Results from a BIOMOL library of 504 bioactive
compounds screened for activator and repressor activi-
ties are shown graphically in Figures 1B and 1C. Second-
ary screening identified two compounds, harmine and
RG14620, as positive regulators and one previously un-
known negative regulator, the kinase inhibitor PP1 (see
Figures S1A–S1C in the Supplemental Data available
with this article online). Of note, a number of previously
characterized inhibitors were also identified in the repres-
sor screen, including various retinoids and prostaglandin F
analogs, validating our approach. Adipocyte differentia-
tion assays by oil red O staining and morphology in both
3T3-F442A and 3T3-L1 cells confirmed the pro- or
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Small-Molecule Regulator of PPARg Expressionantiadipogenic activity of these compounds (Figures 1D
and 1E and data not shown).
Since the activity of the luciferase reporter used in our
screen is highly dependent on PPARg, it was reasonable
to suspect that some of the hits we obtained might be
direct ligands for the receptor. However, harmine was
inactive in transfection assays for PPARg and RXR ligand
activity using chimeric PPARg-GAL4 or RXRa-GAL4
receptors and a luciferase reporter containing GAL4 bind-
ing sites (Forman et al., 1995) (Figure S2). Harmine also
had no effect on the response of PPARg to GW7845 in
this assay, indicating that it is not an antagonist of the
receptor (data not shown). RG14620 activated PPARg
very weakly at high doses, but this activity appears
insufficient to account for its adipogenic action.
Harmine: A Small-Molecule Regulator of PPARg
Expression
At this stage, harmine was selected for further studies.
Gene expression analysis confirmed increased expres-
sion of the adipocyte differentiation-dependent PPARg
target genes aP2, LPL, andCD36 in 3T3-F442A preadipo-
cytes treated with either harmine or GW7845 (Figure 2A).
Rapid induction of these genes by GW7845 on day 1
was consistent with direct activation of PPARg. However,
the effects of harmine were delayed in onset, suggestive
of a more indirect effect. PPARg does not regulate its
own expression directly (Tontonoz et al., 1994), and there-
fore, treatment with GW7845 led to only modest increases
in PPARg mRNA expression secondary to increased
differentiation. Surprisingly, PPARg mRNA and protein
expression were strongly induced by harmine (Figures 2A
and 2B). Consistent with their effects on lipid accumula-
tion (Figure 1), induction of aP2 expression by either
harmine or GW7845 was dose dependent (Figure 2C). In
contrast to harmine, GW7845 had only marginal effects
on PPARg mRNA expression, even at high doses.
Time-course experiments revealed that the induction of
PPARg (both isoforms 1 and 2) by harmine occurred as
early as 4 hr after treatment (Figure 2D). Notably, harmine
did not alter the expression of C/EBPb or C/EBPd, two
transcription factors reported to be upstream of PPARg
in the adipocyte differentiation cascade (Wu et al., 1995,
1996). On the other hand, the standard differentiation
induction cocktail (dexamethasone, IBMX, and insulin;
DMI) upregulated the expression of C/EBPb or C/EBPd
but did not induce PPARg expression at these time points
in 3T3-F442A cells (Figure 2D). Harmine had no effect on
other known positive regulators of differentiation, includ-
ing KLF5 and EBF1 (data not shown). Harmine was also
observed to increase PPARg expression in fully differenti-
ated F442A adipocytes (Figure 2E), although the magni-
tude of this induction was smaller than in preadipocytes.
The induction of PPARg mRNA by harmine is the result
of increased transcription, since it was blocked by actino-
mycin D treatment (Figure 2F). Consistent with the effect
of harmine on 3T3-L1 differentiation, PPARg was also
induced by harmine in 3T3-L1 cells (Figure 2G). In order
to confirm that the magnitude of PPARg induction byCeharmine was sufficient to alter target gene expression in
adipocytes, we ectopically expressed PPARg in 3T3-L1
cells. Indeed, modest increases in PPARg expression in
preadipocytes led to significant increases in both lipid
accumulation and aP2 expression (Figure 2H).
Interestingly, we found that the effect of harmine on
PPARg was cell-type specific. In primary mouse hepato-
cytes, harmine had no effect on expression of either
PPARg or its target genes (aP2 and LPL), while GW7845
induced aP2 and LPL but not PPARg (Figure S3A). On
the other hand, harmine did induce expression of both
PPARg1 and PPARg2 in primary mouse bone-marrow-
derived macrophages (Figure S3B), suggesting that
harmine might promote the anti-inflammatory action of
PPARg in this cell type (see below).
Harmine has previously been reported to interact with
several cell-surface receptors, including monoamine oxi-
dase A (MAO-A) (Kim et al., 1997), serotonin receptor 2A
(5-HT2A) (Glennon et al., 2000), imidazoline receptors
(I1 and I2 sites) (Husbands et al., 2001), and cyclin-
dependent kinases (CDK1, 2, and 5) (Song et al., 2004).
However, none of these appear to be the target for the
metabolic actions of harmine in adipocytes. Highly specific
ligands for MAO-A and MAO-B (clorgyline and deprenyl),
5-HT2A (a-methyl-5-hydroxytryptamine), imidazoline
receptor I1 and I2 sites (clonidine and 2-BFI), and CDKs
(roscovitine) did not promote adipocyte differentiation or
PPARg expression (Figure S4 and data not shown).
We also tested the effect of a combination of harmine
and a maximal dose of GW7845 (100 nM). 3T3-F442A
cells treated with both harmine and GW7845 showed
greater differentiation than cells treated by either com-
pound alone (Figure 2I). Harmine and the PPARg agonist
also showed an additive effect on the expression of the
PPARg target genes aP2 and Adipoq, but not PPARg
itself. Together, the above results demonstrate that har-
mine acts via a mechanism distinct from that of previously
describedadipogenic chemicals, includingPPARgagonists,
cAMP inducers, insulin, and glucocorticoids.
Harmine Is an Inhibitor of Wnt Signaling
in Preadipocytes
Since harmine did not appear to alter known pathways
that promote differentiation, we tested its effect on inhib-
itory pathways. Harmine had no effect on expression of
Pref-1 and Notch1 (data not shown) but showed promi-
nent effects on Wnt signaling in preadipocytes. The Wnt
signaling pathway is a particularly important inhibitor of
differentiation (Ross et al., 2000). Wnt activation blocks
adipocyte differentiation, whereas suppression of the
Wnt pathway promotes differentiation. Activation of
TCF/LEF transcription factors by b-catenin plays a critical
role in the canonical Wnt pathway (Moon et al., 2002). We
found that harmine suppressed the activation of the TOP-
FLASH reporter by LEF1 and active b-catenin in both 293T
cells and preadipocytes (Figure 3A). Harmine also sup-
pressed the activation of LEF1 triggered by the GSK3b
inhibitor LiCl or Wnt-3a (Figure 3B). Furthermore, harmine
blocked the induction of the endogenous Wnt targetll Metabolism 5, 357–370, May 2007 ª2007 Elsevier Inc. 359
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Small-Molecule Regulator of PPARg ExpressionFigure 2. Harmine Is a Specific Inducer of PPARg Expression in Preadipocytes
(A) Gene expression profile during the differentiation of 3T3-F442A cells treated with GW7845 (20 nM) or harmine (10 mM). Cells were treated with
chemicals and insulin (5 mg/ml) at confluence. In this and all other figures, error bars represent SEM.
(B) Induction of PPARg protein expression by harmine. 3T3-F442A cells were treated with harmine (10 mM) and insulin (5 mg/ml) for 6 days. Protein
samples were collected and analyzed by western blotting.
(C) Selective and dose-dependent induction of PPARg2 expression by harmine. 3T3-F442A cells were treated with harmine or GW7845 at the indi-
cated concentration for 5 days.
(D) Comparison of the effects of harmine and the standard differentiation induction cocktail (dexamethasone, IBMX, and insulin; DMI) on early gene
expression change in 3T3-F442A cells. Cells were treated with harmine (10 mM) or DMI (1 mM, 0.5mM, and 5 mg/ml, respectively) for the indicated time
1 day after confluence.
(E) Induction of PPARg expression in 3T3-F442A cells by 48 hr harmine treatment 7 days after induction of differentiation.
(F) Actinomycin D treatment blocks the induction of PPARg2 expression by harmine. One day after confluence, 3T3-F442A cells were pretreated with
actinomycin D (5 mg/ml) 1 hr before harmine treatment (10 mM). RNA was isolated after 12 hr.
(G) Induction of PPARg expression by harmine in 3T3-L1 cells. Cells were treated with harmine (10 mM) in the presence of insulin (5 mg/ml) 1 day after
confluence for 48 hr.
(H) Induction of aP2 expression and lipid accumulation in 3T3-L1 cells overexpressing PPARg. 3T3-L1 cells stably overexpressing PPARgwere gen-
erated as described previously (Tontonoz et al., 1994). Gene expression was measured at confluence. The plate was stained with oil red O on day 7.
(I) Additive effect of harmine and GW7845 on adipocyte differentiation and PPARg target gene expression. Top left: oil red O staining of 3T3-F442A
cells differentiated for 6 days with harmine, a maximal dose of GW7845 (100 nM), or both. Note: Higher doses of GW7845 do not further increase
differentiation in this assay (data not shown). mRNA was collected from duplicate cultures on day 3, and expression of PPARg, aP2, and Adipoq
was determined. Gene expression was analyzed by real-time PCR in all panels.genes axin2,wisp2, and nkd2 by Wnt-3a in preadipocytes
(Figure 3C and data not shown) (Jackson et al., 2005).
Reciprocally, harmine reversedWnt suppression ofPPARg
as well as its target genes aP2, Adipoq, and CD36
(Figure 3C and data not shown). In line with the effects
on gene expression, harmine overcame the inhibitory360 Cell Metabolism 5, 357–370, May 2007 ª2007 Elsevier Inceffect of Wnt-3a or LiCl on adipocyte differentiation as
assessed by oil red O staining and morphology (Figures
3D and 3E).
To further establish that harmine regulation of PPARg is
mediated through inhibition of Wnt signaling, we con-
ducted limited structure-function analysis. We assayed.
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Small-Molecule Regulator of PPARg ExpressionFigure 3. Inhibition of the Wnt Signaling Pathway by Harmine
(A) Harmine (10 mM) suppresses activation of the TOP-FLASH reporter by LEF1 and active b-catenin in 293T cells (left) and 3T3-L1 cells (right).
(B) Harmine suppresses activation of the TOP-FLASH reporter by the GSK3b inhibitor LiCl (25 mM) or Wnt-3a-conditioned medium in 293T cells.
(C) Reversal ofWnt-3a effects onWnt target genes (top), PPARg (middle), and PPARg target genes (bottom) by harmine in 3T3-F442A cells. Cells were
treated with Wnt-3a (10 ng/ml) and harmine (10 mM) 1 day after confluence.
(D and E) Harmine reverses the inhibitory effect of Wnt-3a (D) and LiCl (10 mM) (E) on adipocyte differentiation of 3T3-F442A. Top, microscopic view;
bottom, oil red O staining. I, insulin.six derivatives of harmine to determine the correlation
between adipogenic and Wnt-inhibitory activity (Figure 4A).
Most of these derivatives were inactive in both assays.
Only 6-methoxyharman induced adipogenesis (Figure 4B)
and PPARg expression (Figure 4C), and this was also
the only derivative that showed an inhibitory effect in the
TOP-FLASH assay (Figure 4D). Finally, the magnitude of
induction of PPARg expression and lipid accumulation in
response to harmine was significantly reduced in 3T3-
F442A preadipocytes expressing a dominant-negative
TCF construct (Figures 4E and 4F). Note: This dominant-
negative construct reduces, but does not abolish, Wnt-
stimulated gene expression in these cells (data not
shown). Therefore, the residual effect of harmine could
result from effects on alternative pathways or simply
from suppression of residual Wnt activity. Together, the
data of Figure 3 and Figure 4 demonstrate that the adipo-
genic activity of harmine results, at least in part, from its
ability to block Wnt signaling in adipocytes.CHarmine Mimics the Effects of PPARg Agonists
in Diabetic Mice
Next, we investigated the effect of harmine in vivo. We
treated C57BL/6 mice with vehicle (saline) or harmine
(30 mg/kg) twice per day for 3 days. Consistent with the
in vitro results, expression of PPARg in white adipose tis-
sue (WAT) was induced by harmine treatment (Figure S5).
Furthermore, expression of the PPARg target genes aP2,
CD36, and Adipoq was also elevated in WAT of harmine-
treated mice. Doses higher than 10 mg/kg were required
to observe significant induction of PPARg expression
(data not shown). No differences in hepatic PPARg ex-
pression were observed, however, suggesting that the
effects of harmine on gene expression are tissue specific
(data not shown; see also below).
Given the ability of harmine to mimic TZDs in their ability
to regulate PPARg target genes in adipose tissue, we
asked whether harmine displayed antidiabetic activity.
We treated obese db/db mice (C57BLKS/J background)ell Metabolism 5, 357–370, May 2007 ª2007 Elsevier Inc. 361
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Small-Molecule Regulator of PPARg ExpressionFigure 4. Structure-Function Analysis of Harmine Derivatives in Adipogenesis and Wnt Signaling
(A) Chemical structures of harmine derivatives.
(B and C) Effect of harmine derivatives (all at 10 mM) on adipocyte differentiation and PPARg mRNA expression in 3T3-F442A cells.
(B) Oil red O staining after 6 days.
(C) PPARg2 expression after 48 hr.
(D) Inhibition of LEF1 and active b-catenin-induced TOP-FLASH activity by harmine derivatives in 293T cells.
(E and F) Dominant-negative TCF blunts harmine effects on PPARg expression and differentiation. 3T3-F442A cells stably expressing vector or a
dominant-negative TCF protein (dnTCF) were generated by retroviral transduction.
(E) PPARg expression 24 hr after harmine or vehicle treatment was determined by real-time PCR.
(F) Oil red O staining of cells on day 5 of differentiation was quantitated by measuring the dye extracted in isopropanol with a colorimetric assay
(510 nm).with either vehicle or harmine for 6 weeks. Body weight,
body composition, and food intake were not different
between groups (Figures 5A–5C). At the start of the exper-
iment, themice were not hyperglycemic, but, as expected,
vehicle-treated mice progressed to diabetes over the fol-
lowing 30 days (Figure 5D). Within 2 weeks of treatment,
harmine-treated mice exhibited reduced blood glucose
levels compared to controls, and their development of
hyperglycemia was delayed. Harmine-treated mice also
showed lower levels of both free fatty acids (FFAs) and tri-
glycerides (Figure 5E) after 26 days of harmine treatment.
Moreover, both glucose tolerance and response to insulin
were improved in animals receiving harmine, as deter-
mined by glucose (Figure 5F) and insulin (Figure 5G) toler-
ance tests. Since harmine has been reported to have CNS
effects at doses of 2 mg/kg (Pennes and Hoch, 1957;
Zetler et al., 1972), we tested whether this dose, which
does not induce PPARg expression (data not shown),
was sufficient to affect glucose metabolism. Mice treated362 Cell Metabolism 5, 357–370, May 2007 ª2007 Elsevier Inc.with 2 mg/kg harmine did not show significant decreases
in fasting glucose or increases in glucose tolerance
(Figure 5H and data not shown). We also tested the effect
of a combination of harmine (30 mg/kg) and rosiglitazone
(4 mg/kg). Consistent with our in vitro observations, har-
mine and the PPARg agonist showed an additive effect
on fasting blood glucose levels in vivo (Figure 5I).
Harmine Regulates Metabolic and Inflammatory
Gene Expression In Vivo
The beneficial effects of harmine on metabolic parameters
indb/dbmicecorrelatedwithbeneficial effectsonbothmet-
abolic and inflammatory gene expression in WAT. Expres-
sion of PPARg1 and g2 and their downstream target genes
involved in lipid storage and glucose metabolism such
as aP2, CD36, LPL, GLUT4, Lipin-1a and -1b, C/EBPa,
and Adipoq was increased in WAT of harmine-treated ani-
mals compared to controls (Figure 6A and Figure S6). Fur-
thermore, harmine reduced expression of the inflammatory
Cell Metabolism
Small-Molecule Regulator of PPARg ExpressionFigure 5. Harmine Treatment Ameliorates Insulin Resistance in db/db Mice
(A) Body weight of vehicle- (saline-) and harmine-treated mice. n = 10–11 per group.
(B) Whole-body composition of db/db mice treated with harmine was determined by dual-energy X-ray absorptiometry (DEXA scan) on day 19 of
treatment. n = 12–14 per group.
(C) Food intake presented as amount consumed per mouse per day divided by body weight. n = 10–11 per group.
(D) Time course of glucose levels (16 hr fasting) in db/db mice treated with vehicle or harmine (30 mg/kg, i.p.). n = 10–11 per group.
(E) Free fatty acid and triglyceride levels on day 26 of treatment. n = 10–11 per group.
(F) Glucose tolerance test (GTT) performed on day 23 of treatment. n = 10–11 per group.
(G) Insulin tolerance test (ITT) performed on day 37 of treatment. n = 10–11 per group.
(H) Dose-dependent effect of harmine on GTT performed after 22 days of treatment. n = 8–9 per group.
(I) Additive effect of harmine and rosiglitazone on fasting glucose levels. Glucose levels were measured after 16 hr fasting on day 29 of harmine treat-
ment (30 mg/kg) and day 11 of rosiglitazone treatment (4 mg/kg). n = 7–9 per group. **p < 0.01; *p < 0.05.mediators TNFa, IL-1b, and iNOS, as well as the macro-
phage markers F4/80 and Mac1, suggesting that adipose
tissue inflammation was decreased. Immunohistological
analysis confirmed that macrophage accumulation in
WAT, as assessed by the number of crown-like structures
(Cinti et al., 2005), was indeed reduced by harmine (Figures
6Band6C). The suppressive effect of harmineon inflamma-
tory gene expression and macrophage accumulation is
consistent with previous work showing that PPARg ligands
suppress inflammatory gene expression and reduce mac-
rophage numbers in WAT (Xu et al., 2003).
We also investigated the link betweenWnt signaling and
the tissue specificity of harmine on PPARg expression
in vivo. We found that expression of the Wnt target geneCwisp2 was significantly reduced in adipose tissue of
mice treated with harmine (Figure 6D), consistent with
the in vitro inhibition ofWnt signaling by harmine (Figure 3).
The suppression of wisp2 by harmine, however, was not
restricted to WAT but was also seen in other tissues
such as skeletal muscle and liver (Figure 6D). This obser-
vation suggests that the tissue-specific effects of harmine
on PPARg expression cannot be explained by tissue-
specific inhibition of the Wnt pathway. We next investi-
gated the tissue specificity of Wnt effects on PPARg
expression. Treatment of 3T3-F442A preadipocytes, pri-
mary hepatocytes, and C2C12 myocytes with Wnt-3a
resulted in induction of the Wnt target genes wisp2,
axin2, and nkd2 in all three cell types (Figure 6E). However,ell Metabolism 5, 357–370, May 2007 ª2007 Elsevier Inc. 363
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Small-Molecule Regulator of PPARg ExpressionFigure 6. Harmine Treatment Induces Expression of PPARg and Its Target Genes and Suppresses Adipose Tissue Inflammation
In Vivo
(A) Gene expression in epididymal white adipose tissue (WAT) was determined by real-time PCR on day 43. n = 10–11 per group. Dots and bars in
scatter plots represent individual mice and the average, respectively.
(B) Immunohistochemistry of epididymal WAT of db/dbmice treated with harmine (day 43) with anti-Mac2 antibody. Arrowheads indicate crown-like
structures, necrotic adipocytes surrounded by macrophages (Cinti et al., 2005).
(C) Quantification of the number of crown-like structures in epididymal WAT. Data are presented as number per mm2. n = 6 per group.
(D) Expression of the Wnt target gene wisp2 in WAT, skeletal muscle (SKM), and liver of mice treated with harmine (30 mg/kg, i.p., twice per day) for
3 days was analyzed by real-time PCR. n = 10 per group.
(E) Effect of Wnt or harmine treatment on PPARg expression in 3T3-F442A cells, primary hepatocytes, and C2C12 myocytes. Cells were treated with
either Wnt-3a-conditioned medium or harmine (10 mM) for the indicated time. Gene expression was analyzed by real-time PCR. **p < 0.01; *p < 0.05.Wnt activation suppressed PPARg expression only in
preadipocytes, and harmine induced PPARg expression
only in preadipocytes. These data strongly suggest that
the tissue-specific effect of harmine onPPARg expression
results from tissue-selective effects of theWnt pathway on
the PPARg gene.
Harmine Promotes Fatty Acid Oxidation and Energy
Expenditure
Interestingly, harmine also increased expression of PGC-
1a and PPAR target genes involved in fatty acid oxidation
in WAT, such as acyl-CoA oxidase (Acox1), LCAD,MCAD,
and CTP-1b, as well as genes involved in energy dissipa-
tion and adoptive thermogenesis, such as UCP1 and
UCP3 (Figure S6). All of these gene expression changes
also occur in response to PPARg ligands, further empha-
sizing the similarity of harmine and PPARg ligand effects
(Way et al., 2001). Previous studies have shown that
induction of these genes by PPARs and PGC-1a is asso-
ciated with increased energy expenditure (Kamei et al.,364 Cell Metabolism 5, 357–370, May 2007 ª2007 Elsevier Inc.2003; Picard et al., 2002; Rothwell et al., 1987; Tanaka
et al., 2003; Uno et al., 2006; Wang et al., 2003). Consis-
tent with the induction of these genes by harmine, indirect
calorimetry demonstrated increased oxygen consumption
and heat production in harmine-treated mice, but no
change in physical activity (Figure 7). Harmine treatment
did not significantly alter expression of a number of other
genes examined, including C/EBPb, C/EBPd, PPARd, and
UCP2 (Figure S6 and data not shown). Expression of resis-
tin (Steppan et al., 2001) was not altered by harmine, and
RBP4 (Yang et al., 2005) was increased, suggesting that
these factors are not mediators of harmine effects on
systemic metabolism.
In contrast to the multiple effects observed in WAT, har-
mine had little effect on gene expression linked to glucose
metabolism in other key metabolic tissues including liver,
brown adipose tissue (BAT), and skeletal muscle (Figures
S7–S9). There was a trend toward increased PPARg2
expression in BAT, but this did not achieve statistical sig-
nificance. Harmine did not alter genes involved in hepatic
Cell Metabolism
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tion on Energy Expenditure in Diabetic
Mice
Oxygen consumption, heat production, and
activity were measured over 3 days by indirect
calorimetry using theOxymaxLabAnimalMon-
itoring System. Mice (five 10-week-old db/db
males per group) were individually housed
and allowed to acclimate in the experimental
cages with free access to food and water.
Animals were maintained on 12 hr light/dark
cycles. Mice were treated daily with vehicle or 30 mg/kg harmine for 2 weeks prior to the experiment, and treatment continued during the experiment.
Data on heat production (calculated from gas exchange data; kcal/mass/time), VO2 (volume of oxygen consumed; ml/mass/time), and activity (XYZ
coverage; total activity counts) were analyzed using the OxymaxWin v3.32 software package. Statistical comparisons of repeated measurements
were made using ANOVA. For ease of presentation, data are expressed as area under the curve (AUC) calculated for the light and the dark period
over the 3 recording days; statistical comparison of these totals was made using Student’s t test. *p < 0.05.glucose production, did not increase expression of ther-
mogenic genes in BAT, and did not increase expression
of genes involved in glucose uptake or fatty acid oxidation
in skeletal muscle. The lack of significant harmine effects
on these pathways is consistent with WAT being the
primary target of its metabolic actions.
Harmine Does Not Share Hepatic and Renal Side
Effects of Thiazolidinediones
The tissue specificity of harmine action suggested that
this compound might not share some of the established
side effects of TZDs. One of undesirable side effects of
TZD treatment is weight gain. Unlike TZD treatment, we
did not observe a significant difference in body weight
within the time frame of this study (Figure 5A). Recent
data indicate that fluid retention caused by activation of
PPARg in the kidney accounts for a significant fraction
of short-term weight gain in TZD-treated mice (Guan
et al., 2005; Zhang et al., 2005). Harmine did not alter
the expression of PPARg or PPARg target genes including
aP2, LPL, and ENaCg in the kidney (Figure S10A). TZDs
have also been shown to increase the number of small ad-
ipocytes in WAT, presumably by promoting differentiation
(Okuno et al., 1998). On histological examination, WAT
from PPARg ligand-treated mice exhibited reduced adi-
pocyte size as expected; however, harmine did not have
a significant influence on adipocyte size in our studies
(data not shown). The lack of an obvious effect of harmine
on differentiation in vivo despite effects on glucose toler-
ance is consistent with modest activation of the PPARg
pathway: low-dose treatment with the PPARg ligand pio-
glitazone (10 mg/kg) or a partial PPARg agonist is suffi-
cient to improve glucose tolerance without inducing
adipocyte differentiation in vivo (Berger et al., 2003;
Kubota et al., 2006; Rocchi et al., 2001). TZDs have also
been shown to promote hepatic triglyceride accumulation
in diabetic mice due to activation of PPARg in the liver
(Chao et al., 2000; Matsusue et al., 2003). In line with the
inability of harmine to regulate PPARg expression in liver
(Figure S10B), however, harmine did not promote hepatic
lipid accumulation in db/db mice, an established side
effect of TZDs (Figure S10C).CDISCUSSION
The development of new drugs for the treatment of insulin
resistance is an important goal of metabolic research. In
this paper, we have outlined a cell-based strategy for
the identification of metabolic regulators. We developed
an assay for adipocyte differentiation that is amenable to
high-throughput screening, and we used this assay to
identify a particularly interesting compound, harmine.
The idea that stimulators of adipogenesis could be bene-
ficial in diabetes is somewhat counterintuitive given the
association of obesity with insulin resistance. However,
strong support for this idea came from the unexpected
discovery that the antidiabetic thiazolidinediones were
ligands for the adipogenic transcription factor PPARg
(Lehmann et al., 1995). We have now provided a second
example of a small molecule that both promotes adipo-
cyte differentiation in vitro and improves glucose tolerance
in vivo. The biological activities of harmine and TZDs under-
score the fact that links between adipose tissue and insulin
resistance are complex and are likely to involve not only
changes in adipose tissue differentiation and cell number
but also changes in adipocyte function. Our results vali-
date phenotypic screening for modulators of adipogene-
sis as a promising approach to the discovery of new
metabolic drugs.
Historically, deciphering the mechanism of action of
small molecules identified through phenotypic screening
has often brought new insights into biology (Schreiber,
2003). Such was the case for TZDs, which were first iden-
tified as compounds that improved insulin sensitivity in
rodents and only later recognized to be agonists for
PPARg (Lehmann et al., 1995; Schreiber, 2003). This dis-
covery led to the elucidation of PPARg as a key player in
the pathophysiology of insulin resistance (Evans et al.,
2004; Lehrke and Lazar, 2005). Our characterization of
the biological activities of harmine has shed light on the
relationship between Wnt signaling, PPARg expression,
and glucose metabolism. To our knowledge, cell-type-
selective small-molecule regulators of PPARg expression
have not been described previously. Although most drug
discovery efforts in this area are focused on the identifi-
cation of new receptor ligands, previous studies usingell Metabolism 5, 357–370, May 2007 ª2007 Elsevier Inc. 365
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alteration of PPARg expression levels can also impact in-
sulin sensitivity (He et al., 2003; Kubota et al., 1999; Miles
et al., 2000). Our results extend this idea by showing that
a small-molecule regulator of PPARg expression can
improve glucose metabolism in diabetic animals. The dis-
covery that PPARg expression in adipose tissue can be
regulated pharmacologically opens the door to new strat-
egies for the development of metabolic drugs.
Although the precise protein target remains to be iden-
tified, considerable evidence suggests that the metabolic
effects of harmine in diabetic mice result at least in part
from activation of the PPARg pathway. First, harmine
induces expression of PPARg and its target genes in
multiple preadipocyte cell lines without affecting the ex-
pression of other adipogenic factors such as C/EBPb
andKLF5. Second, harmine induces expression ofPPARg
in adipose tissue in vivo, an activity not shared with any
other small molecule to our knowledge. Third, the effects
of harmine on gene expression in adipose tissue are
virtually identical to the effects of TZDs (Way et al.,
2001). Harmine and TZDs regulate the expression of the
same battery of PPARg target genes involved in fatty
acid metabolism (transport, storage, synthesis, and
oxidation) and energy dissipation (Way et al., 2001).
Fourth, harmine mimics the effects of TZDs on inflamma-
tion in adipose tissue. Similar to TZDs, harmine attenuates
inflammatory gene expression and macrophage accumu-
lation in adipose tissue, which has been proposed to con-
tribute to obesity-induced insulin resistance (Hotamisligil,
2006; Neels and Olefsky, 2006; Xu et al., 2003). Fifth, har-
mine induces energy expenditure in diabetic mice as
previously reported for TZDs. Sixth, harmine’s efficacy
at lowering glucose levels and regulating adipocyte gene
expression is consistent with other weak activators of
the PPARg pathway such as partial agonists (Berger
et al., 2003; Rocchi et al., 2001). Seventh, regulation of
PPARg target gene expression in adipose is known to
be critical for the actions of TZDs on glucose and lipid
metabolism (Evans et al., 2004). Therefore, the metabolic
effects of harmine are consistent with well-established
links between adipocyte gene expression and systemic
metabolism. Finally, the metabolic effects of harmine can-
not be explained by changes in gene expression in liver or
skeletal muscle. Thus, regulation of the PPARg pathway in
adipose tissue provides a highly plausible explanation for
the metabolic effects of harmine.
Structure-function studies and gene expression analy-
sis suggest that harmine exerts its metabolic effects at
least in part through inhibition of Wnt signaling. Harmine
inhibits Wnt-dependent gene expression in adipocyte
cell lines and adipose tissue and reverses the inhibitory
effect of Wnt agonists on differentiation and PPARg ex-
pression. Interestingly, the tissue specificity of harmine’s
effects on PPARg expression appears to result from
cell-type-specific effects of Wnt signaling. For example,
harmine inhibits Wnt signaling in muscle as well as fat,
but Wnt does not control PPARg expression in muscle.
These observations suggest that other inhibitors of the366 Cell Metabolism 5, 357–370, May 2007 ª2007 Elsevier Inc.Wnt signaling pathway could be also candidates for anti-
diabetic drugs. Furthermore, since a number of different
transcription factors and signaling pathways are likely to
converge on the regulation of PPARg expression in adipo-
cytes, it may be possible to identify additional small-mol-
ecule regulators of PPARg expression with distinct mech-
anisms of action.
Harmine is a b-carboline alkaloid that was first isolated
in 1847 from seeds of Peganum harmala (Syrian rue) and
Banisteriopsis caapi, both of which have traditionally
been used for ritual andmedicinal preparations in theMid-
dle East, Central Asia, and South America (Sourkes,
1999). It is also present in common plant-derived foods
and in human tissues (Guan et al., 2001). To our knowl-
edge, the ability of harmine to modulate glucose metabo-
lism and/or diabetes has not been explored previously.
Known pharmacologic effects of harmine include halluci-
nogenesis (Sourkes, 1999), convulsive or anticonvulsive
actions (Aricioglu et al., 2003), and tremorogenesis
(Guan et al., 2001; Lutes et al., 1988). Consistent with
these reports, we observed a transient tremor following
harmine administration to which the animals developed
resistance after the first few doses (Lutes et al., 1988).
No other side effects of harmine administration were ob-
served in our studies. Clearly, given its CNS side effects,
harmine itself is not a suitable candidate for drug develop-
ment. However, it may eventually be possible to separate
the CNS andmetabolic effects of harmine through optimi-
zation of the chemical structure.
Several potential molecular targets for the central phar-
macologic effects of harmine have been identified. These
include MAO-A (Kim et al., 1997), 5-HT2A (Glennon et al.,
2000), imidazoline receptors (I1 and I2 sites) (Husbands
et al., 2001), and cyclin-dependent kinases (CDK1, 2,
and 5) (Song et al., 2004). However, none of these appear
to be the target for the metabolic actions of harmine in ad-
ipocytes. Highly specific ligands for these receptors did
not share the ability to promote adipocyte differentiation
or PPARg expression (Figure S4 and data not shown). Fur-
thermore, 6-methoxyharman, which promoted adipocyte
differentiation and PPARg expression, does not bind 5-
HT2A receptors (Figure 4) (Glennon et al., 2000).
Nevertheless, given the fact that harmine is known to
have CNS targets and the fact that CNS pathways regu-
late peripheral glucose and lipid metabolism, the possibil-
ity that CNS actions may contribute to the metabolic ef-
fects of harmine must be considered. Substrates of
MAO-A include neurotransmitters such as serotonin, his-
tamine, and catecholamines (Youdim et al., 2006). Cate-
cholamines are known to stimulate gluconeogenesis in
the liver; stimulate lipolysis and FFA release in adipose tis-
sue; and increase glucose uptake in muscle, WAT, and
BAT (Nonogaki, 2000). Chronic intracerebroventricular in-
jection of histamine induces lipolysis and UCP1 expres-
sion in BAT and UCP3 expression in WAT (Masaki et al.,
2001). 5-HT2A agonists have been reported to reduce
food intake and increase oxygen consumption (Bovetto
and Richard, 1995; Nonogaki, 2000). The imidazoline re-
ceptor I1 and I2 sites have been proposed to mediate
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late sodium excretion in kidney, and modulate behavioral
effects of morphine (Husbands et al., 2001). However, the
overall metabolic effects of harmine are not consistent
with activation of any of these CNS targets in vivo. For ex-
ample, MAO inhibitors and selective serotonin reuptake
inhibitors (SSRIs) have been widely used as antidepres-
sants for decades, and there has been no report of an
antidiabetic effect of these drugs (Ferguson, 2001; Youdim
et al., 2006). Furthermore, although increased expression
of UCP1 and UCP3 in WAT and higher oxygen consump-
tion in harmine-treated mice could be explained by sym-
pathetic tone in the autonomous nervous system, the
lack of an effect of harmine on regulation of genes involved
in gluconeogenesis in the liver, as well as the lack of
evidence of increased lipolysis in adipose tissue (higher
FFA levels), argues against this interpretation. We also
did not observe a change in the activity of harmine-treated
mice in energy-expenditure studies as might be expected
with sympathetic activation. Nevertheless, identification
of the molecular target of harmine’s metabolic effects
will be required in order to completely rule out these
possibilities.
In conclusion, we have validated phenotypic screening
of adipocytes as a promising approach to the discovery of
antidiabetic small molecules. Furthermore, we have linked
two biological activities with the antidiabetic actions of
this compound: control of PPARg mRNA expression and
inhibition of Wnt signaling. Our results suggest that other
small molecules that share these activities may be candi-
dates for metabolic drugs. Moreover, given their distinct
mechanism of action and side-effect profile, drugs acting
through these pathways may represent a complementary
approach to PPARg ligands for the treatment of insulin
resistance.
EXPERIMENTAL PROCEDURES
Reagents and Plasmids
GW7845 was provided by T. Willson (GlaxoSmithKline). LG268 was
provided by R. Heyman (Ligand Pharmaceuticals). Harmine hydro-
chloride and LiCl were purchased from Sigma (#H0625 and #L0505).
RG14620 and PP1 were from BIOMOL International LP (#EI253-0005
and #EI275). Harmine hydrochloride and RG14620 were dissolved in
water and DMSO, respectively. Insulin (#I0516), dexamethasone
(#D2915), and 3-isobutyl-1-methylxanthine (IBMX, #I7018) were from
Sigma. Actinomycin D was from Calbiochem. Purified Wnt-3a protein
was from R&D Systems (#1324-WN). Plasmids encoding Gal4-DBD
fusions of mPPARg-LBD (pCMX-Gal4-mPPARg-LBD), hRXRa-LBD
(pCMX-hRXRa-LBD), reporter gene pMH-100-TK-luc, and pCMX-b-
gal were described previously (Forman et al., 1995). A luciferase
reporter under the control of the 5.4 kb aP2 promoter (Ross et al.,
1990) (pGL3-aP2-Luc) was generated by cloning the promoter, ampli-
fied by primers 50- ATTCCCAGCAGGAATCAGGTAGCTGGAG-30 and
50-ACAGGAGGGTGCTATGAG-30, into the KpnI-NheI sites of pGL3-
Basic (Promega).
Cell Culture
HEK293T cells were cultured in DMEM with 10% fetal bovine serum
(FBS) with antibiotics at 37C and 5% CO2. 3T3-F442A and 3T3-L1
preadipocytes were maintained in DMEM supplemented with 10%
calf serum. For differentiation of 3T3-F442A, cells were cultured inCDMEM with 10% FBS and treated with insulin (5 mg/ml) at confluence.
For 3T3-L1, cells were treated with dexamethasone (1 mM), IBMX
(0.5 mM), and insulin (5 mg/ml) for 2 days after confluence, followed
by treatment with insulin alone. Other chemicals and purified Wnt-3a
were added as indicated in legends. For Wnt-3a-conditioned media,
Wnt-3a-expressing L cells or control L cells (ATCC) were cultured in
DMEM with 10% FBS, and medium was collected as described at
http://www.atcc.org/common/catalog/numSearch/numResults.cfm?
atccNum=CRL-2647. Mouse primary hepatocytes were isolated from
2- to 3-month-old male C57BL/6 mice and cultured using the BioCoat
Hepatocyte Differentiation Environment system (Becton Dickinson) as
described in Pei et al. (2006). Bone marrow-derived macrophages
were isolated as described elsewhere (Castrillo et al., 2003). Briefly,
bone marrow isolated from femur and tibia was treated with red blood
cell lysis buffer (Sigma R7757), washed with PBS, resuspended in
DMEM supplemented with 20% FBS and 30% conditioned medium
from L929 cells expressing macrophage colony-stimulating factor
(M-CSF), and plated in six-well plates at density of 1 3 106 cells per
well. Cells were used for experiments after a 5 day incubation. Retro-
viral overexpression of PPARg2 was performed using pBabe puro-
PPARg2 and the packaging cell line Phoenix E as described elsewhere
(Tontonoz et al., 1994). For generation of F442-luc20 cells, 3T3-F442A
cells were cotransfected with pGL3-aP2-Luc (72 mg) and pSV2-bsr
(1.2 mg) using Lipofectamine 2000. Blasticidin S-resistant colonies
were isolated on day 11 and expanded. Luciferase activity during
differentiation was determined, and clone #20 (F442-luc20) was
selected based on the robustness and differentiation dependence of
luciferase activity.
Cell-Based Chemical Screening
F442-luc20 cells (2000/well) were plated into 96-well plates in 180 ml
DMEM with 10% FBS and antibiotics. Three days later, when cells
were 90% confluent, the libraries were transferred using a pin tool.
On the next day, 20 ml medium containing insulin was added to the
medium (final concentration 5 mg/ml). On day 5 after confluence, cells
were lysed in 30 ml of Cell Culture Lysis Reagent (Promega), and lucif-
erase activity was determined using the Luciferase Assay System
(Promega). Small-molecule libraries were obtained from BIOMOL
and used according to the manufacturer’s recommendations. They
included 72 ion channel inhibitors (#2805), 84 kinase/phosphatase
inhibitors (#2831), 84 orphan ligands (#2825), 60 endocannabinoids
(#2801), and 204 bioactive lipids (#2800). The compounds were
dissolved in the manufacturer-recommended solvent and stored at
80C in 384 wells.
RNA and Protein Analysis
Total RNAwas isolated using TRIzol reagent (Invitrogen). 0.5 mg of total
RNA was reverse transcribed using MultiScribe (Applied Biosystems)
and random hexamers according to the manufacturer’s instructions.
Real-time quantitative PCR (SYBR green) analysis was performed on
a 7900HT Fast Real-Time PCR System (Applied Biosystems). Primer
sequences are listed in Table S1. Expression was normalized to
36B4. For RNA from adipose tissue, homogenized TRIzol samples
were centrifuged and the lipid layer was removed. After dissolving
RNA into DEPC-treated water, phenol-chloroform extraction was
performed twice followed by ethanol precipitation. Forty nanograms
of total RNA was reverse transcribed using the iScript cDNA Synthesis
Kit (Bio-Rad). Protein preparation, SDS-PAGE, and western blotting
were performed as previously described (Waki et al., 2003). Equal
amounts of protein were loaded. Antiserum against murine PPARg
was a kind gift from B.M. Spiegelman (Dana-Farber Cancer Institute).
Luciferase Reporter Assays
For chimeric PPARg-GAL4 assay, HEK293T cells (1 3 105 cells per
well) were plated in 48-well plates in 250 ml of DMEM (2% FBS) without
antibiotics. The next day, cells were cotransfected with pCMX-Gal-
mPPARg-LBD, pMH-100-TK-luc, and pCMX-b-gal using Lipofect-
amine 2000 (Invitrogen). One day later, chemicals were added to theell Metabolism 5, 357–370, May 2007 ª2007 Elsevier Inc. 367
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Reagent (Promega), and luciferase activity was determined using the
Luciferase Assay System (Promega). Luciferase value was normalized
to b-galactosidase activity. TOP-FLASH assays were performed as
previously described (Korinek et al., 1997; Morin et al., 1997).
HEK293T cells (5 3 106 cells) were plated in 10 cm plates in DMEM
(10% FBS) without antibiotics. The next day, cells were cotransfected
with plasmids for TOP-FLASH, LEF1, constitutively active mutant
b-catenin (S37A), and renilla luciferase using Lipofectamine 2000.
Eighteen hours later, cells were trypsinized, centrifuged, and resus-
pended in fresh DMEM with 10% FBS. Cells were replated in 24-well
plates at 1:2 dilution and treated with either harmine (or derivatives),
LiCl, or Wnt-3a-conditioned media for 24 hr. Firefly and renilla lucifer-
ase were measured using the Dual-Luciferase Reporter Assay System
(Promega) according to themanufacturer’s instructions. Firefly luciferase
value was normalized to renilla luciferase.
Animals
C57BLKS/J-Leprdb/db and C57BL/6 wild-type mice were purchased
from The Jackson Laboratory. Nine-week-old male db/db mice were
randomized into two groups according to glucose levels and body
weight and treated with daily intraperitoneal (i.p.) injection of harmine
(30 mg/kg) or saline. Harmine was dissolved in sterile saline (150 mM
NaCl) at 3 mg/ml and stored at 20C. Prior to use, the harmine solu-
tion was warmed in a 42C water bath with agitation. For wild-type
mice, 16-week-old C57BL/6 mice were treated with harmine (30 mg/kg,
i.p.) twice per day. For troglitazone treatment, mice were fed chow
containing troglitazone (0.4%). For blood analysis, db/db mice were
fasted for 16 hr and blood was collected from the tail vein. Glucose
levels were determined using an Accu-Chek Active glucometer
(Roche). Free fatty acid levels were determined by the NEFA C test
kit (Wako). Triglyceride levels were determined by the Serum Triglycer-
ide Determination Kit (Sigma). Insulin levels were determined using an
Ultra Sensitive Rat Insulin ELISA Kit (Crystal Chem Inc.). For glucose
tolerance tests, mice were fasted for 16 hr, and glucose levels from
tail-vein blood were determined before and 30, 60, 90, and 120 min
after i.p. injection of glucose (2 g/kg). For insulin tolerance tests,
random fed mice were injected i.p. with insulin (Humulin R, Eli Lilly)
(2 U/kg). Glucose levels were determined before and 30, 60, 120,
180, and 210 min after injection. Animal studies were conducted in
accordance with the Animal Research Committee of the University of
California, Los Angeles.
Indirect Calorimetry
Oxygen consumption, heat production, and activity were measured
over 3 days using the Oxymax Lab Animal Monitoring System (Colum-
bus Instruments). Mice (five 10-week-old db/dbmales per group) were
individually housed and allowed to acclimate in the experimental
cages with free access to food and water. Animals were maintained
on a 12 hr light/dark cycle and were treated with vehicle or harmine
(30 mg/kg) for 17 days prior to the start of the experiment. During the
experiment, mice were dosed daily with vehicle or harmine as de-
scribed above. Data was analyzed using the OxymaxWin v3.32 soft-
ware package. Statistical comparisons of repeated measurements
were made using ANOVA. For ease of presentation, data are ex-
pressed as area under the curve (AUC) calculated for the light and
the dark period over the 3 recording days; statistical comparison of
these totals was made using Student’s t test. All experiments were
approved by the Institutional Animal Use and Care Committee of The
Genomics Institute of the Novartis Research Foundation.
Histological Analysis of Adipose Tissue
White adipose tissue was fixed with paraformaldehyde, dehydrated,
and embedded in paraffin, and 10 mm thick sections were subjected
to hematoxylin-and-eosin staining. For immunohistochemistry, slides
containing 5 mm sections were baked at 60C for 30 min to melt the
paraffin. The slides were deparaffinized with xylene and rehydrated
through graded ethanol. Endogenous peroxidase activity was blocked368 Cell Metabolism 5, 357–370, May 2007 ª2007 Elsevier Inc.with 3% hydrogen peroxide in methanol for 10 min. Antigen retrieval
was performed by boiling the slides for 25 min at 95C in 0.01 M so-
dium citrate buffer (pH 6.0). Purified rat anti-mouse Mac2 antibody
(Cedarlane Laboratories, CL8942AP, clone M3/38) was applied at
1:5000 concentration overnight at 4C. Slides were subsequently
incubated with anti-rat biotinylated secondary antibody at 1:200 con-
centration (eBioscience, #13-4813-85). Histochemical reactions were
performed using the VECTASTAIN ABC Kit (Vector Laboratories,
#PK6100) and diaminobenzidine (DAB), and the slides were counter-
stained with hematoxylin.
Supplemental Data
Supplemental Data include ten figures and one table and can be found
with this article online at http://www.cellmetabolism.org/cgi/content/
full/5/5/357/DC1/.
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